O	0	8	Clinical
O	9	23	classification
O	24	26	of
B-Disease	27	30	age
I-Disease	30	31	-
I-Disease	31	38	related
I-Disease	39	46	macular
I-Disease	47	59	degeneration
O	59	60	.

O	62	64	To
O	65	72	develop
O	73	74	a
O	75	83	clinical
O	84	98	classification
O	99	105	system
O	106	109	for
B-Disease	110	113	age
I-Disease	113	114	-
I-Disease	114	121	related
I-Disease	122	129	macular
I-Disease	130	142	degeneration
O	143	144	(
B-Disease	144	147	AMD
O	147	148	)
O	148	149	.

O	150	158	Evidence
O	158	159	-
O	159	164	based
O	165	178	investigation
O	178	179	,
O	180	185	using
O	186	187	a
O	188	196	modified
O	197	203	Delphi
O	204	211	process
O	211	212	.

O	213	219	Twenty
O	219	220	-
O	220	223	six
B-Disease	224	227	AMD
O	228	235	experts
O	235	236	,
O	237	238	1
O	239	244	neuro
O	244	245	-
O	245	260	ophthalmologist
O	260	261	,
O	262	263	2
O	264	273	committee
O	274	282	chairmen
O	282	283	,
O	284	287	and
O	288	289	1
O	290	303	methodologist
O	303	304	.

O	305	309	Each
O	310	319	committee
O	320	326	member
O	327	336	completed
O	337	339	an
O	340	346	online
O	347	357	assessment
O	358	360	of
O	361	371	statements
O	372	383	summarizing
O	384	391	current
B-Disease	392	395	AMD
O	396	410	classification
O	411	419	criteria
O	419	420	,
O	421	431	indicating
O	432	441	agreement
O	442	444	or
O	445	457	disagreement
O	458	462	with
O	463	467	each
O	468	477	statement
O	478	480	on
O	481	482	a
O	483	484	9
O	484	485	-
O	485	489	step
O	490	495	scale
O	495	496	.

O	497	500	The
O	501	506	group
O	507	510	met
O	510	511	,
O	512	520	reviewed
O	521	524	the
O	525	531	survey
O	532	539	results
O	539	540	,
O	541	550	discussed
O	551	554	the
O	555	564	important
O	565	575	components
O	576	578	of
O	579	580	a
O	581	589	clinical
O	590	604	classification
O	605	611	system
O	611	612	,
O	613	616	and
O	617	624	defined
O	625	628	new
O	629	633	data
O	634	642	analyses
O	643	649	needed
O	650	652	to
O	653	659	refine
O	660	661	a
O	662	676	classification
O	677	683	system
O	683	684	.

O	685	690	After
O	691	694	the
O	695	702	meeting
O	702	703	,
O	704	714	additional
O	715	719	data
O	720	728	analyses
O	729	733	from
O	734	739	large
O	740	747	studies
O	748	752	were
O	753	761	provided
O	762	764	to
O	765	768	the
O	769	778	committee
O	779	781	to
O	782	789	provide
O	790	794	risk
O	795	804	estimates
O	805	812	related
O	813	815	to
O	816	819	the
O	820	828	presence
O	829	831	of
O	832	839	various
B-Symptom	840	843	AMD
I-Symptom	844	851	lesions
O	851	852	.

O	853	859	Delphi
O	860	866	review
O	867	869	of
O	870	873	the
O	874	875	9
O	875	876	-
O	876	880	item
O	881	884	set
O	885	887	of
O	888	898	statements
O	899	908	resulting
O	909	913	from
O	914	917	the
O	918	925	meeting
O	925	926	.

O	927	936	Consensus
O	937	940	was
O	941	949	achieved
O	950	952	in
O	953	963	generating
O	964	965	a
O	966	971	basic
O	972	980	clinical
O	981	995	classification
O	996	1002	system
O	1003	1008	based
O	1009	1011	on
B-Symptom	1012	1018	fundus
I-Symptom	1019	1026	lesions
O	1027	1035	assessed
B-Anatomy	1036	1042	within
I-Anatomy	1043	1044	2
I-Anatomy	1045	1049	disc
I-Anatomy	1050	1059	diameters
I-Anatomy	1060	1062	of
I-Anatomy	1063	1066	the
I-Anatomy	1067	1072	fovea
O	1073	1075	in
O	1076	1083	persons
B-Characteristic	1084	1089	older
I-Characteristic	1090	1094	than
I-Characteristic	1095	1097	55
I-Characteristic	1098	1103	years
O	1103	1104	.

O	1105	1108	The
O	1109	1118	committee
O	1119	1125	agreed
O	1126	1130	that
O	1131	1132	a
O	1133	1139	single
O	1140	1144	term
O	1144	1145	,
B-Disease	1146	1149	age
I-Disease	1149	1150	-
I-Disease	1150	1157	related
I-Disease	1158	1165	macular
I-Disease	1166	1178	degeneration
O	1178	1179	,
O	1180	1186	should
O	1187	1189	be
O	1190	1194	used
O	1195	1198	for
O	1199	1202	the
O	1203	1210	disease
O	1210	1211	.

O	1212	1219	Persons
O	1220	1224	with
O	1225	1227	no
O	1228	1235	visible
B-Symptom	1236	1242	drusen
O	1243	1245	or
B-Symptom	1246	1256	pigmentary
I-Symptom	1257	1270	abnormalities
O	1271	1277	should
O	1278	1280	be
O	1281	1291	considered
O	1292	1294	to
O	1295	1299	have
O	1300	1302	no
O	1303	1308	signs
O	1309	1311	of
B-Disease	1312	1315	AMD
O	1315	1316	.

O	1317	1324	Persons
O	1325	1329	with
B-Symptom	1330	1335	small
I-Symptom	1336	1342	drusen
O	1343	1344	(
B-Dimension	1345	1346	<
I-Dimension	1347	1349	63
I-Dimension	1350	1351	μ
I-Dimension	1351	1352	m
O	1352	1353	)
O	1353	1354	,
O	1355	1359	also
O	1360	1366	termed
B-Symptom	1367	1376	drupelets
O	1376	1377	,
O	1378	1384	should
O	1385	1387	be
O	1388	1398	considered
O	1399	1401	to
O	1402	1406	have
B-Disease	1407	1413	normal
I-Disease	1414	1419	aging
O	1420	1427	changes
O	1428	1432	with
O	1433	1435	no
O	1436	1446	clinically
O	1447	1455	relevant
O	1456	1465	increased
O	1466	1470	risk
O	1471	1473	of
B-Disease	1474	1478	late
I-Disease	1479	1482	AMD
O	1483	1493	developing
O	1493	1494	.

O	1495	1502	Persons
O	1503	1507	with
B-Symptom	1508	1514	medium
I-Symptom	1515	1521	drusen
O	1522	1523	(
B-Dimension	1523	1524	≥
I-Dimension	1525	1527	63
I-Dimension	1527	1528	-
I-Dimension	1529	1530	<
I-Dimension	1531	1534	125
I-Dimension	1535	1536	μ
I-Dimension	1536	1537	m
O	1537	1538	)
O	1538	1539	,
O	1540	1543	but
O	1544	1551	without
B-Symptom	1552	1562	pigmentary
I-Symptom	1563	1576	abnormalities
O	1577	1584	thought
O	1585	1587	to
O	1588	1590	be
O	1591	1598	related
O	1599	1601	to
B-Disease	1602	1605	AMD
O	1605	1606	,
O	1607	1613	should
O	1614	1616	be
O	1617	1627	considered
O	1628	1630	to
O	1631	1635	have
B-Disease	1636	1641	early
I-Disease	1642	1645	AMD
O	1645	1646	.

O	1647	1654	Persons
O	1655	1659	with
B-Symptom	1660	1665	large
I-Symptom	1666	1672	drusen
O	1673	1675	or
O	1676	1680	with
B-Symptom	1681	1691	pigmentary
I-Symptom	1692	1705	abnormalities
I-Symptom	1706	1716	associated
I-Symptom	1717	1721	with
I-Symptom	1722	1724	at
I-Symptom	1725	1730	least
I-Symptom	1731	1737	medium
I-Symptom	1738	1744	drusen
O	1745	1751	should
O	1752	1754	be
O	1755	1765	considered
O	1766	1768	to
O	1769	1773	have
B-Disease	1774	1786	intermediate
I-Disease	1787	1790	AMD
O	1790	1791	.

O	1792	1799	Persons
O	1800	1804	with
B-Symptom	1805	1812	lesions
I-Symptom	1813	1823	associated
I-Symptom	1824	1828	with
I-Symptom	1829	1840	neovascular
I-Symptom	1841	1844	AMD
O	1845	1847	or
B-Symptom	1848	1858	geographic
I-Symptom	1859	1866	atrophy
O	1867	1873	should
O	1874	1876	be
O	1877	1887	considered
O	1888	1890	to
O	1891	1895	have
B-Disease	1896	1900	late
I-Disease	1901	1904	AMD
O	1904	1905	.

O	1906	1910	Five
O	1910	1911	-
O	1911	1915	year
O	1916	1921	risks
O	1922	1924	of
O	1925	1936	progressing
O	1937	1939	to
B-Disease	1940	1944	late
I-Disease	1945	1948	AMD
O	1949	1952	are
O	1953	1962	estimated
O	1963	1965	to
O	1966	1974	increase
O	1975	1988	approximately
O	1989	1992	100
O	1993	1997	fold
O	1997	1998	,
O	1999	2006	ranging
O	2007	2011	from
O	2012	2013	a
O	2014	2015	0
O	2015	2016	.
O	2016	2017	5
O	2017	2018	%
O	2019	2020	5
O	2020	2021	-
O	2021	2025	year
O	2026	2030	risk
O	2031	2034	for
B-Disease	2035	2041	normal
I-Disease	2042	2047	aging
O	2048	2055	changes
O	2056	2058	to
O	2059	2060	a
O	2061	2063	50
O	2063	2064	%
O	2065	2069	risk
O	2070	2073	for
O	2074	2077	the
O	2078	2085	highest
B-Disease	2086	2098	intermediate
I-Disease	2099	2102	AMD
O	2103	2107	risk
O	2108	2113	group
O	2113	2114	.

O	2115	2118	The
O	2119	2127	proposed
O	2128	2133	basic
O	2134	2142	clinical
O	2143	2157	classification
O	2158	2163	scale
O	2164	2169	seems
O	2170	2172	to
O	2173	2175	be
O	2176	2178	of
O	2179	2184	value
O	2185	2187	in
O	2188	2198	predicting
O	2199	2202	the
O	2203	2207	risk
O	2208	2210	of
B-Disease	2211	2215	late
I-Disease	2216	2219	AMD
O	2219	2220	.

O	2221	2234	Incorporating
O	2235	2245	consistent
O	2246	2258	nomenclature
O	2259	2263	into
O	2264	2267	the
O	2268	2276	practice
O	2277	2285	patterns
O	2286	2288	of
O	2289	2292	all
B-Anatomy	2293	2296	eye
O	2297	2301	care
O	2302	2311	providers
O	2312	2315	may
O	2316	2323	improve
O	2324	2337	communication
O	2338	2341	and
O	2342	2349	patient
O	2350	2354	care
O	2354	2355	.
